Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Milosevic

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
British Journal of Cancer|August 9, 2012
Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment responseJ W Thoms, A Dal Pra, P H Anborgh, et al.
Current Oncology (Toronto, Ont.)|December 23, 2017
Strategic planning in an academic radiation medicine programJ L Hamilton, S Foxcroft, E Moyo, et al.
Micromachines|February 25, 2022
Ge Ion Implanted Photonic Devices and Annealing for Emerging ApplicationsXingshi Yu, Xia Chen, Milan M Milosevic, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|May 11, 2020
Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients - control survival is much better than previously assumedM Milosevic, J Edwards, D Tsang, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical CystectomyP J Boström, J Thoms, J Sykes, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
British Journal of Cancer|August 9, 2012
Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment responseJ W Thoms, A Dal Pra, P H Anborgh, et al.
Current Oncology (Toronto, Ont.)|December 23, 2017
Strategic planning in an academic radiation medicine programJ L Hamilton, S Foxcroft, E Moyo, et al.
Micromachines|February 25, 2022
Ge Ion Implanted Photonic Devices and Annealing for Emerging ApplicationsXingshi Yu, Xia Chen, Milan M Milosevic, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|May 11, 2020
Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients - control survival is much better than previously assumedM Milosevic, J Edwards, D Tsang, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical CystectomyP J Boström, J Thoms, J Sykes, et al.
Pageof 9